Directorio

We are doing this study to learn more about how brain cell activity guides memory and navigation.

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

We are doing this study to learn more about spasticity that some people experience after they have a stroke. Spasticity is a condition where muscles involuntarily stiffen and aren't as strong as they should be. We want to better understand when this happens after a stroke, what parts of the body are most likely to be affected, and how the symptoms affect people.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.

People in this study will have tests before they start. These tests include blood work, a heart check called an electrocardiogram, pictures of the heart, a chest x-ray, and answering questions on forms. If they can join, they will be put into one of two groups by chance. One group will get a medicine called XC001, and the other group will get a placebo. Both will be given as shots into the heart muscle during surgery. After surgery, there will be check-up visits at 2 weeks, and then at 1, 3, 6, and 12 months. These visits will include the same tests as before.

We are doing this study to find out if surgically removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing melanoma from coming back in the same area of the lymph node excision. We also want to learn more about the side effects of this type of surgery and how it can impact patients' quality of life.